Derek Lewis, MD
Family Medicine · Little Rock, ARNPI 1407810641
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,678 of the $7,456 with a category attached, or 62.7%. 36 manufacturers reported payments, led by Modernatx, Inc. at 24.4% of the total. Reporting peaked in 2024 at $2,055 and has fallen 58.2% since, to $858 in 2025. Among family medicine clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $41.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$2K
- Boehringer Ingelheim International GmbH$1K
- Boehringer Ingelheim$623
- Pfizer$357
- GSK$278
- AbbVie$276
- plus $3K from 30 others
Across 720 payments — averaging $2496.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$601K
- Valneva Austria GmbH$326K
- Bavarian Nordic A/s$180K
- Boehringer Ingelheim$180K
- Seqirus USA Inc$176K
- Novavax Inc$139K
- plus $196K from 17 others
What the payments were for
- Travel & lodging$2,77837%
- Food & beverage$4,67863%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 4 | $1,817 |
| Boehringer Ingelheim International GmbH | 11 | $1,386 |
| Boehringer Ingelheim | 10 | $623 |
| Pfizer | 23 | $357 |
| GSK | 18 | $278 |
| AbbVie(2 entities) | 11 | $276 |
| Global Blood Therapeutics, Inc. | 14 | $269 |
| Biotronik Inc. | 5 | $232 |
| AstraZeneca | 6 | $197 |
| Lilly USA, LLC | 11 | $191 |
| Novartis | 6 | $173 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $158 |
| Johnson & Johnson | 6 | $157 |
| Nevro Corp. | 8 | $129 |
| Novo Nordisk | 3 | $128 |
| MDD US Operations, LLC | 1 | $128 |
| Gilead | 1 | $125 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $117 |
| Amarin Pharma, Inc. | 1 | $116 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $110 |
| Abbott | 1 | $98 |
| Ferring Pharmaceuticals Inc. | 1 | $84 |
| Esperion Therapeutics, Inc. | 4 | $54 |
| Sanofi-aventis U.S. LLC | 4 | $49 |
| Bayer | 2 | $30 |
| Amgen | 2 | $27 |
| Boston Scientific | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Globus Medical | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
| Sanofi | 1 | $13 |
| Impel Pharmaceuticals Inc. | 1 | $12 |
| Biodelivery Sciences International, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Lucemyra/Lofexidine$128
- LOKELMA$125
- Descovy$125
- Vascepa$116
- Tresiba$114
- XARELTO$112
- TRINTELLIX$110
How this compares
$7,456 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 283 | $285,443 |
| EliquisApixaban | 135 | $150,308 |
| EntrestoSacubitril/Valsartan | 49 | $57,679 |
| JardianceEmpagliflozin | 55 | $54,265 |
| LinzessLinaclotide | 44 | $36,552 |
| MounjaroTirzepatide | 24 | $26,207 |
| TrulicityDulaglutide | 28 | $24,217 |
| JanuviaSitagliptin Phosphate | 22 | $19,830 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $18,076 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 416 | $13,421 |
| XareltoRivaroxaban | 17 | $13,335 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $12,729 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 103 | $11,182 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $10,961 |
| SymbicortBudesonide/Formoterol Fumarate | 26 | $9,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Levemir | $128 | $287,689295 claims |
| PfizerEliquis | $357 | $150,308135 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $623 | $60,80566 claims |
| NovartisEntresto | $173 | $57,67949 claims |
| Lilly USA, LLCMounjaro, Trulicity | $191 | $50,42452 claims |
| AbbVieLinzess | $276 | $36,55244 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $278 | $35,77358 claims |
| Johnson & JohnsonXarelto | $157 | $13,33517 claims |
| AstraZenecaSymbicort | $197 | $9,60026 claims |
| Sanofi-aventis U.S. LLCLantus | $49 | $2,27332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Little Rock
- Harold BettonLittle Rock$18K
- Kevin RobertsLittle Rock$15K
- Sanjay DassLittle Rock$14K
- Benjamin McDonaldLittle Rock$14K
- Oksana MelnykLittle Rock$12K
- Thomas MooreLittle Rock$11K
- Patrick FieldsLittle Rock$10K
- Gilbert FosterLittle Rock$10K
- Glenn GibbonsFort Smith$179K
- Hetal PatelParagould$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.